华润医药(03320.HK)旗下美索巴莫注射液获得药品注册证书

阿斯达克财经
23 Jan

华润医药(03320.HK) 宣布,旗下华润双鹤利民药业(济南)有限公司收到国家药品监督管理局颁发的美索巴莫注射液《药品注册证书》,并视同通过一致性评价。

美索巴莫注射液用于急性骨骼肌疼痛或不适症状的治疗。根据米内网数据显示,2023年中国医疗市场和零售市场美索巴莫注射液销售总额(终端价)为3.29亿元人民币。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-23 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10